Supplemental material
Human Vaccines & Immunotherapeutics
Volume 17, 2021 - Issue 4
Research Paper
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
Shangying Hua Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
https://orcid.org/0000-0002-4778-1612View further author information
https://orcid.org/0000-0002-4778-1612View further author information, Xiaoqian Xua Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinahttps://orcid.org/0000-0001-9269-2283View further author information
https://orcid.org/0000-0001-9269-2283View further author information, , , , , , , , , , , , , , Naveen Karkadah GSK, Clinical Research & Development, Wavre, Belgiumhttps://orcid.org/0000-0002-7543-1345View further author information
https://orcid.org/0000-0002-7543-1345View further author information, , Dan Bih GSK, Clinical Research & Development, Wavre, Belgiumhttps://orcid.org/0000-0003-0426-4639View further author information
https://orcid.org/0000-0003-0426-4639View further author information, Frank Struyfj GSK, Wavre, Belgium at the Time This Analysis Was Performed. Current Affiliation: Janssen Research & Development, Beerse, Belgiumhttps://orcid.org/0000-0001-9988-0260View further author information
https://orcid.org/0000-0001-9988-0260View further author information & show all